Study reveals extremely low detection of SARS-CoV-2 on surfaces in oncology facilities
Researchers from Rutgers Cancer Institute of New Jersey, the state s only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.
The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor. Andrew M. Evens, DO, MSc, FACP, associate director for clinical services and director of the Lymphoma Program at Rutgers Cancer Institute and medical director of the oncology service line at RWJBarnabas Health, is senior author of the work, which has been published in the February 18 online edition of
Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.
Researchers from Rutgers Cancer Institute of New Jersey, the state s only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.
E-Mail
IMAGE: Lance Liotta, MD, PhD, study PI, and George Mason University College of Science CAPMM co-founder and co-director. view more
Credit: Evan Cantwell, George Mason University
A George Mason University and Rutgers Cancer Institute of New Jersey collaboration received the U.S. Army s Breast Cancer Research Program (BCRP) Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments.
George Mason University s College of Science announced an exciting $1.33 million collaboration with Rutgers Cancer Institute of New Jersey and Mason s Center for Applied Proteomics and Molecular Medicine (CAPMM) which taps cancer research diagnostics and treatment strengths within the medical facilities and CAP/CLIA laboratory respectively of the two regional powerhouses.